17R-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid | 901116-76-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 17R-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid
• 英文别名: 17R H(p)DHA；(4Z,7Z,10Z,13Z,15E,17R,19Z)-17-hydroperoxydocosa-4,7,10,13,15,19-hexaenoic acid
• CAS: 901116-76-5
• 化学式: C₂₂H₃₂O₄
• 分子量: 360.494
• InChiKey: BNHQALRBDJVUQB-NGHKTGSUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  26
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  17R-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid 在 15-lipoxygenase soybean 作用下， 生成 16,17R-epoxy-HDHA
  参考文献：
  名称：

  [EN] USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  [FR] UTILISATION DE DOCOSATRIENES, RESOLVINES ET LEURS ANALOGUES STABLES POUR LE TRAITEMENT DE MALADIES DES VOIES RESPIRATOIRES ET DE L'ASTHME

  摘要：

  公开号：

  WO2005089744A3
• 作为产物：
  描述：

  二十二碳六烯酸 在 Sorangium cellulosum arachidonate 15R-lipoxygenase, wild type 作用下， 以 aq. buffer 为溶剂， 生成 17R-hydroperoxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid
  参考文献：
  名称：

  Biotransformation of C20- and C22-polyunsaturated fatty acids and fish oil hydrolyzates to R,R-dihydroxy fatty acids as lipid mediators using double-oxygenating 15R-lipoxygenase

  摘要：

  C20- 和 C22-二羟基脂肪酸（DiHFAs）是人体中具有生物活性的脂质介质（LMs）。

  DOI：

  10.1039/d4gc00308j

文献信息

• WO2006/78457
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] RESOLVINS: BIOTEMPLATES FOR THERAPEUTIC INTERVENTIONS<br/>[FR] LES RESOLVINES, DES GABARITS BIOLOGIQUES CONVENANT POUR DE NOUVELLES INTERVENTIONS THERAPEUTIQUES
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2004014835A3

  公开（公告）日：2004-04-15
• Use of Docosatrienes, Resolvins and Their Stable Analogs in the Treatment of Airway Diseases and Asthma
  申请人：Serhan N. Charles

  公开号：US20080096961A1

  公开（公告）日：2008-04-24

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
• DOCOSAHEXANOIC ACID AS INHIBITOR OF H. PYLORI
  申请人：Touati Eliette

  公开号：US20110064789A1

  公开（公告）日：2011-03-17

  The present invention concerns a method for preventing, modulating or curing in a mammal, the infections with Helicobacter pylori or the symptoms associated with H. pylori infection(s) or related diseases, and/or improving the clinical condition of a mammal infected with H. pylori, or affected by a related disease, comprising administering to a mammal in need thereof an effective amount of one or more DHA related compounds, as well as their use as an adjuvant or co-adjuvant in a method for preventing, modulating or curing in a mammal, the chronical infection with Helicobacter pylori or the symptoms associated with H. pylori infection or related diseases, and/or preventing recurrence as well as relapse of H. pylori infection or related diseases, and/or improving the clinical condition of a mammal infected with H. pylori.
• USE OF DOCOSATRIENES, RESOLVINS, AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  申请人：Serhan Charles N.

  公开号：US20120264713A1

  公开（公告）日：2012-10-18

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.